Company
LON:HEMO
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
128 stories · page 3 of 7
Investments and investor services
Hemogenyx thinks its new ApbHC mouse model could be used to rapidly develop antibodies to treat deadly pathogens such as Anthrax released as an act of war
Archive
Aside from the two mid-cap transport operators, blue chip contractor Bunzl will also issue a trading update, while the macro focus will be on the G20 meeting in Japan
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A look at the day's major movers, including Big Sofa Technologies, Techfinancials, Paragon Entertainment, Pendragon, Metro Bank, Serco, Taptica, HemoGenyx Pharmaceuticals ...
Investments and investor services
"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”
Archive
The UK's premier shares index finished the afternoon session off nearly 31 points at 7,367
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
A look at some of the biggest risers and fallers in London on Wednesday
Investments and investor services
Vladislav Sandler, the company’s chief executive, said the firm was “encouraged” by the results
Investments and investor services
The UK blue-chip share index finished up around four points at 7,218
Investments and investor services
A look at the day's major movers, including Aptitude Software, Watches of Switzerland, Veltyco, Johnson Matthey, Nuformix, HemoGenyx, De La Rue and Real Good Food
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
“This antibody should, if successful, provide a new and potentially effective treatment for a form of blood cancer for which adult survival rates are currently very poor," said CEO Vladislav Sandler
Investments and investor services
The FTSE 100 closed 32.86 points higher at 7,218.16 on Thursday, just easing off its late afternoon high of 7,235
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
The AIM-listed group last year signed an agreement with a global bio-pharmaceutical company to develop its CDX antibodies under a potential for licensing deal
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland
Archive
A look at the day's major movers, including Kibo Energy, Red Rose, Red Emperor Resources, Anglo African Oil & Gas, Mobile Streams, Dunelm and Ted Baker
